🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

12 recruiting trials

for Metastatic HER2 Positive Gastroesophageal Junction Cancer

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) NCT06730373Phase 220 sites📍 Zhengzhou📍 Binzhou📍 Dongying Qilu Hospital of Shandong University · Tests: Disitamab Vedotin, Sintilimab, S-1, Trastuzumab, Oxaliplatin KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy NCT05427383Phase 2, Phase 31 site📍 Beijing Shanghai JMT-Bio Inc. · Tests: KN026/Placbo Injection, Paclitaxel Injection, Docetaxel Injection, Irinotecan Injection IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer NCT07025889Phase 1, Phase 21 site📍 Shanghai Ruijin Hospital · Tests: IBI343, Sintilimab, Oxaliplatin, S-1 A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer NCT06532006Phase 3208 sites📍 Anaheim📍 Los Alamitos📍 Greeley Shanghai Henlius Biotech · Tests: HLX22, Pembrolizumab, Trastuzumab, Oxaliplatin, Capecitabine Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients NCT06650332Phase 1, Phase 21 site📍 Hangzhou Zhejiang Cancer Hospital · Tests: cadonilimab, Trastuzumab, XELOX, Disitamab Vedotin, mFOLFOX6 A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer NCT06901531Phase 3252 sites📍 Birmingham📍 Bakersfield📍 Cerritos Astellas Pharma Global Development, Inc. · Tests: zolbetuximab, Pembrolizumab, Capecitabine, Oxaliplatin, Folinic acid (leucovorin or local equivalent) M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. NCT06177041Phase 31 site📍 Beijing FutureGen Biopharmaceutical (Beijing) Co., Ltd · Tests: M108 monoclonal antibody, Placebo, Oxaliplatin, Capecitabine SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen NCT06123494Phase 31 site📍 Shanghai Jiangsu HengRui Medicine Co., Ltd. · Tests: SHR-A1811, Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer NCT07673887Phase 38 sites📍 Saint Louis Park📍 Guangzhou📍 Guangzhou Astellas Pharma Global Development, Inc. · Tests: ASP2138, Pembrolizumab, Oxaliplatin, Capecitabine, Folinic acid Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 NCT07431281Phase 3314 sites📍 Birmingham📍 Mobile📍 Anchorage AstraZeneca · Tests: Sonesitatug vedotin, Rilvegostomig, Nivolumab, Capecitabine, 5-Fluorouracil Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China NCT06846996n/a40 sites📍 Beijing📍 Beijing📍 Beijing Daiichi Sankyo · Tests: Trastuzumab deruxtecan (T-DXd) Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer NCT06731478Phase 3250 sites📍 New Haven📍 Skokie📍 Kansas City Daiichi Sankyo · Tests: Trastuzumab Deruxtecan, pembrolizumab, Trastuzumab, Chemotherapy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy